Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Effective inhibition of plasma kallikrein may have significant benefits for patients with hereditary angioedema due to deficiency of C1 inhibitor (C1‐INH‐HAE) by reducing the frequency of angioedema attacks. Avoralstat is a small molecule inhibitor of plasma kallikrein. This study (OPuS‐2) evaluated the efficacy and safety of prophylactic avoralstat 300 or 500 mg compared with placebo. A total of 110 subjects were randomized and dosed.
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Hereditary angioedema (HAE) caused by C1 inhibitor deficiency (C1-INH-HAE) is characterized by recurrent episodes of disabling swelling. Recombinant human C1 inhibitor (rhC1-INH) is approved for treatment of HAE attacks. A treatment registry was established in Europe to review the safety and efficacy of rhC1-INH.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
